Author(s)

Hao Tang, Chun Huang^*

Affiliation(s)

Department of Cardiothoracic Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.

Corresponding Author

Chun Huang

ABSTRACT

To evaluate the predictive value of reactive cutaneous capillary endothelial proliferation (RCCEP) in the treatment outcome of patients with first-diagnosed advanced esophageal squamous cell carcinoma (ESCC) treated with camrelizumab in combination with chemotherapy. This is a single-center, retrospective, observational study of 76 patients who were first diagnosed with advanced ESCC and received Camrelizumab combination chemotherapy at our institution from January 2021 to December 2022, and were compared between those who had and those who did not have an RCCEP response to determine the predictive value of an RCCEP response for treatment outcomes in this patient population.The overall survival (OR) of patients with RCCEP response was 15.08 ± 6.35 months, which was better than that of patients without RCCEP response of 10.55 ± 4.68 months, and the difference was statistically significant (P=0.001). Twenty-eight cases (77.78%) of the patients who experienced partial response (PR), while the overall response rate (ORR) was 77.78%; while among the patients who did not experienced RCCEP response, only five cases (12.50%) experienced PR, and the ORR was 12.50%, which were statistically different in both cases (P<0.001; P<0.001). There was no difference in the occurrence of treatment-related adverse events between the two groups. Meanwhile, 88.89% of RCCEP patients experienced grade Ⅰ response, 11.11% experienced grade Ⅱ response, and no grade Ⅲ-Ⅴ response occurred. 66.67% of RCCEP patients showed red-nevus-like.The occurrence of RCCEP suggests therapeutic efficacy in patients with advanced ESCC treated with camrelizumab in combination with chemotherapy, indicating the prognostic value, and may serve as a potential predictor of treatment outcome in this patient population.

KEYWORDS

Esophageal Squamous Cell Carcinoma; Reactive cutaneous capillary endothelial proliferation; Camrelizumab; Immune-related adverse events; Advanced esophageal carcinoma

CITE THIS PAPER

Hao Tang, Chun Huang. Predictive value of RCCEP in the outcome of patients with advanced esophageal squamous cell carcinoma treated with CAMRELIZUMAB. Journal of Pharmaceutical and Medical Research. 2024, 6(2): 16-22. DOI: 10.61784/jpmrv6n292.

REFERENCES

[1] SUNG H, FERLAY J, SIEGEL R L, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 2021, 71(3): 209-49.

[2] CAO W, CHEN H D, YU Y W, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl), 2021, 134(7): 783-91.

[3] LAGERGREN J, SMYTH E, CUNNINGHAM D, et al. Oesophageal cancer. Lancet, 2017, 390(10110): 2383-96.

[4] FAN Y J, SONG X, LI J L, et al. Esophageal and gastric cardia cancers on 4238 Chinese patients residing in municipal and rural regions: a histopathological comparison during 24-year period. World J Surg, 2008, 32(9): 1980-8.

[5] LU C L, LANG H C, LUO J C, et al. Increasing trend of the incidence of esophageal squamous cell carcinoma, but not adenocarcinoma, in Taiwan. Cancer Causes Control, 2010, 21(2): 269-74.

[6] GUO J C, HUANG T C, LIN C C, et al. Postchemoradiotherapy Pathologic Stage Classified by the American Joint Committee on the Cancer Staging System Predicts Prognosis of Patients with Locally Advanced Esophageal Squamous Cell Carcinoma. J Thorac Oncol, 2015, 10(10): 1481-9.

[7] CHEN W W, LIN C C, HUANG T C, et al. Prognostic factors of metastatic or recurrent esophageal squamous cell carcinoma in patients receiving three-drug combination chemotherapy. Anticancer Res, 2013, 33(9): 4123-8.

[8] LUO H, LU J, BAI Y, et al. Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial. JAMA, 2021, 326(10): 916-25.

[9] AJANI J A, MOISEYENKO V M, TJULANDIN S, et al. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol, 2007, 25(22): 3205-9.

[10] ROSENBERG J E, HOFFMAN-CENSITS J, POWLES T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet, 2016, 387(10031): 1909-20.

[11] KAUFMAN H L, RUSSELL J, HAMID O, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol, 2016, 17(10): 1374-85.

[12] ROBERT C, LONG G V, BRADY B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med, 2015, 372(4): 320-30.

[13] HERBST R S, BAAS P, KIM D W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet, 2016, 387(10027): 1540-50.

[14] KATO K, CHO B C, TAKAHASHI M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol, 2019, 20(11): 1506-17.

[15] WANG F, QIN S, SUN X, et al. Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial. J Hematol Oncol, 2020, 13(1): 47.

[16] ZHAO Y N, CONG D, ZHANG W, et al. Immune-related adverse events as independent prognostic factors for camrelizumab in patients with esophageal squamous cell carcinoma: a retrospective cohort study. J Gastrointest Oncol, 2023, 14(2): 733-43.

[17] CHEN W, ZHENG R, BAADE P D, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-32.

[18] ENZINGER P C, MAYER R J. Esophageal cancer. N Engl J Med, 2003, 349(23): 2241-52.

[19] WANG X, HOBBS B, GANDHI S J, et al. Current status and application of proton therapy for esophageal cancer. Radiother Oncol, 2021, 164: 27-36.

[20] XU Y, FU Y, ZHU B, et al. Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities. Front Immunol, 2020, 11: 2023.

[21] POSTOW M A, SIDLOW R, HELLMANN M D. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med, 2018, 378(2): 158-68.

[22] BAGCHI S, YUAN R, ENGLEMAN E G. Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. Annu Rev Pathol, 2021, 16: 223-49.

[23] BAXI S, YANG A, GENNARELLI R L, et al. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ, 2018, 360: k793.

[24] HUA C, BOUSSEMART L, MATEUS C, et al. Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab. JAMA Dermatol, 2016, 152(1): 45-51.

[25] FRIEDMAN C F, PROVERBS-SINGH T A, POSTOW M A. Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review. JAMA Oncol, 2016, 2(10): 1346-53.

[26] BELUM V R, BENHURI B, POSTOW M A, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer, 2016, 60: 12-25.

[27] XU J, ZHANG Y, JIA R, et al. Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study. Clin Cancer Res, 2019, 25(2): 515-23.

[28] FANG W, YANG Y, MA Y, et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol, 2018, 19(10): 1338-50.

[29] SERNA-HIGUITA L M, AMARAL T, FORSCHNER A, et al. Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry. Cancers (Basel), 2021, 13(23).